Conference Coverage

Anastrozole provides alternative option for DCIS


 

AT THE 2015 ASCO ANNUAL MEETING

References

Dr. Don Dizon Susan London/Frontline Medical News

Dr. Don Dizon

ASCO expert Dr. Don Dizon agreed and said the results of B-35 answer a very important clinical question and will allow physicians who treat women with DCIS to counsel them on an individual level about their treatment options.

The study was funded by the National Institutes of Health. Dr. Margolese reported no relevant conflicts of interest. Dr. Dizon reported employment and a consultant or advisory board role with UpToDate and research funding to his institution from AstraZeneca and GlaxoSmithKline.

pwendling@frontlinemedcom.com

On Twitter @pwendl

Pages

Recommended Reading

Contamination prompts voluntary injectables recall
MDedge ObGyn
Exercise pumps up chemotherapy completion rates for breast cancer patients
MDedge ObGyn
AACR: Targeted combo active in triple-negative breast cancer, ovarian cancer
MDedge ObGyn
Omega-3 fatty acids similar to placebo for aromatase inhibitor–induced musculoskeletal pain
MDedge ObGyn
Mammographic breast density is a strong risk factor for breast cancer
MDedge ObGyn
ASA: Radiation lowers local recurrence risk for DCIS patients with close or positive margins
MDedge ObGyn
Similar 5-year outcomes from accelerated partial-breast irradiation, whole-breast irradiation
MDedge ObGyn
Neoadjuvant chemotherapy for triple negative breast cancer improves conservation
MDedge ObGyn
A quarter of women with dense breasts at high interval cancer risk
MDedge ObGyn
ACOG spells out risk assessment for hereditary cancer syndromes
MDedge ObGyn